rs1154404 — ADH5 ADH5 Asthma Risk Haplotype Variant

Intronic variant in ADH5 (GSNOR) in near-complete LD (r²=0.99) with adjacent promoter SNPs at a potential NF-κB binding site; the common A allele tags the asthma risk haplotype associated with elevated GSNOR transcription, GSNO depletion, and increased childhood asthma susceptibility, while the protective T allele is associated with reduced GSNOR expression and lower asthma risk

See your personal result for ADH5

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ADH5 rs1154404 — The Hidden Regulator of Airway Nitric Oxide

Every breath you take depends on a delicate balance between molecules that keep bronchial smooth muscle relaxed and inflammatory signals that tighten it. S-nitrosoglutathione (GSNO)11 S-nitrosoglutathione (GSNO)
GSNO is the predominant bioactive form of nitric oxide in airway lining fluid; it relaxes smooth muscle at nanomolar concentrations and is 100-fold more potent than the asthma drug theophylline as a bronchodilator is one of the lung's most powerful endogenous bronchodilators — and its concentration in the airways is controlled by a single enzyme, ADH5, officially known as S-nitrosoglutathione reductase (GSNOR). The rs1154404 variant sits in intron 1 of the ADH5 gene on chromosome 4 and serves as a proxy for nearby promoter variants that determine how much GSNOR the airways produce. The common A allele (plus-strand) tags a high-GSNOR-expression haplotype associated with elevated childhood asthma risk; the rarer T allele marks the protective low-expression end of the spectrum.

The Mechanism

GSNOR breaks down GSNO irreversibly, converting it to oxidized glutathione and ammonia. When GSNOR expression is elevated — as in the A-allele risk haplotype — airway GSNO levels fall, smooth muscle tone rises, and the lung loses its intrinsic bronchodilator reserve. This mechanism was confirmed directly in human lung: Que et al. 200922 Que et al. 2009
GSNOR activity measured from BAL fluid in 13 asthmatic and 11 healthy adults; asthmatic samples showed GSNOR activity 1,223 vs 537 AU/mg protein found GSNOR activity more than doubled in asthmatic airways compared to healthy controls, while total S-nitrosothiol levels were halved. GSNOR activity correlated inversely with methacholine PC20 (r = 0.54, P = 0.008) — the tighter the enzyme grip on GSNO, the more hyperresponsive the airway.

rs1154404 itself is an intronic variant (intron 1 of ADH5) and does not change the GSNOR protein sequence. Its functional significance comes from being in near-complete linkage disequilibrium33 near-complete linkage disequilibrium
LD r²=0.99, meaning this SNP almost always co-inherits with adjacent promoter variants across generations with two adjacent promoter SNPs — rs2602899 and rs2851301 — that sit within a putative NF-κB binding site44 NF-κB binding site
NF-κB (nuclear factor kappa-B) is a master inflammatory transcription factor that, when active, drives expression of dozens of inflammation genes including GSNOR in the ADH5 promoter. The A allele is believed to preserve this NF-κB site intact, supporting higher GSNOR transcription in response to inflammatory signalling. The T allele disrupts the site, reducing GSNOR output and leaving more GSNO available as a bronchodilator.

ADH5 also clears formaldehyde — a ubiquitous environmental irritant from new furniture, pressed-wood building materials, and cigarette smoke — by metabolising the spontaneous formaldehyde-glutathione adduct S-hydroxymethylglutathione. When environmental formaldehyde load is high, it competes for the same enzyme capacity as GSNO, further depleting airway GSNO55 further depleting airway GSNO
Thompson & Grafström 2008 — mechanistic analysis of how formaldehyde competes with GSNO for GSNOR enzyme capacity in the airway and potentially worsening bronchoconstriction — a dual-substrate competition that is most consequential in A-allele carriers whose GSNOR baseline is already elevated.

The Evidence

The primary genetic study by Wu et al. 200766 Wu et al. 2007
Journal of Allergy and Clinical Immunology; 532 nuclear families with asthmatic children aged 4–17, Mexico City; case-parent triad design removes population stratification enrolled 532 Mexican families with asthmatic children and genotyped seven GSNOR SNPs including rs1154404. Carrying one copy of the protective T allele was associated with a 23% reduced relative risk of asthma (RR 0.77, 95% CI 0.61–0.97, P = 0.028); carrying two copies reduced risk by 34% (RR 0.66, 95% CI 0.44–0.99, P = 0.046). Haplotype analysis confirmed the direction: the risk haplotype containing the A allele at rs1154404 carried RR 1.57 (P = 0.017) for asthma. Strikingly, these allele effects were not associated with degree of atopy (IgE levels, positive skin tests) — the GSNOR-GSNO axis affects airway smooth muscle tone independently of the classical IgE-mediated allergic cascade, pointing to a distinct non-atopic pathway to asthma susceptibility.

A 2017 review by Barnett & Buxton77 Barnett & Buxton
Critical Reviews in Biochemistry and Molecular Biology; comprehensive synthesis of GSNOR biology and therapeutic targeting across multiple diseases validates the clinical significance: ADH5-null (knockout) mice show elevated airway S-nitrosothiol levels and are protected from allergen-induced airway hyperresponsiveness. This knockout phenotype — protective against asthma — is the molecular mirror image of what the A-allele risk haplotype produces in humans. The therapeutic direction is clear enough that GSNOR inhibitor N6022 entered Phase 2 clinical trials for asthma, with early signals of bronchial hyperreactivity improvement.

A pharmacogenomic layer emerges from Choudhry et al. 201088 Choudhry et al. 2010
The Pharmacogenomics Journal; 609 Latino asthmatic trios from the GALA cohort; functional cell transfection experiments confirmed risk haplotype gain-of-function for GSNOR expression: GSNOR risk alleles interact with the ADRB2 Arg16Gly variant (rs1042713) to impair bronchodilator response to albuterol. Combined GSNOR + ADRB2 multi-locus genotyping achieved 70% predictive value for lack of response to albuterol in status asthmaticus, a clinically actionable pharmacogenomic signal.

The primary limitation of current evidence is that the genetic association derives from a single study in a Latin American pediatric cohort, with replication in European or Asian populations still lacking. This keeps the evidence level at moderate despite a compelling functional mechanism and therapeutic confirmation.

Practical Actions

The rs1154404 A-allele risk haplotype operates through a mechanism distinct from allergic sensitisation: it impairs the airway's intrinsic bronchodilator reserve via GSNO depletion. This means conventional allergy management (antihistamines, IgE reduction) does not address the root issue. Interventions that restore airway nitric oxide availability — through dietary nitrate and GSNO-sparing strategies — are mechanistically targeted to this variant. Formaldehyde exposure is a uniquely relevant trigger because it competes directly for the enzyme whose overactivity the A allele drives, compounding the GSNO deficit.

Interactions

rs28730619 (also in ADH5) is the companion variant on the same asthma risk haplotype: the C allele at rs28730619 combined with the A allele here marks the highest-risk GSNOR haplotype identified in Wu et al. 2007. The two variants are partially in LD and the risk haplotype is defined by their co-inheritance.

The ADRB2 Arg16Gly variant (rs1042713) interacts with the GSNOR risk haplotype to predict bronchodilator response to albuterol — carriers of both risk configurations show the most impaired acute beta-agonist response. This gene-gene interaction is clinically actionable: combined GSNOR + ADRB2 genotyping explains approximately 70% of albuterol non-response in status asthmaticus in paediatric cohorts.

Genotype Interpretations

What each possible genotype means for this variant.

TT Protective Homozygote Beneficial

Two copies of the protective allele — lowest GSNOR-mediated asthma risk with maximum airway GSNO reserve from this variant

You carry two copies of the T (protective) allele at rs1154404, found in approximately 10% of people globally. The T allele disrupts a putative NF-κB binding site in the ADH5 promoter, reducing GSNOR transcription on both chromosomes. Lower GSNOR activity means airway S-nitrosoglutathione (GSNO) is degraded more slowly, preserving the lung's endogenous bronchodilator reserve. The primary study found that carrying two copies of the protective allele was associated with 34% reduced childhood asthma risk (RR 0.66, 95% CI 0.44–0.99, P=0.046). From this variant specifically, your GSNOR-GSNO axis contributes favourably to airway health.

AT One Protective Allele Intermediate

One copy of the protective allele — reduced asthma risk compared to AA homozygotes with partial GSNOR-GSNO buffering capacity

The additive dose-response pattern (AA > AT > TT) means your intermediate risk falls between the AA homozygote (highest GSNOR activity, lowest GSNO, greatest asthma risk) and the TT protective homozygote. Your airways have partial buffering capacity for GSNO — one chromosome maintains a higher-GSNOR-expression promoter, while the other chromosome reduces GSNOR output via the disrupted NF-κB site.

The formaldehyde-GSNO enzyme competition is still relevant for heterozygotes: while your GSNOR activity is intermediate, high environmental formaldehyde loads can still erode airway GSNO, particularly in enclosed spaces with new particleboard materials or during renovation.

AA Risk Haplotype Homozygote High Risk

Two copies of the GSNOR risk allele — elevated asthma susceptibility from chronically higher GSNOR activity and reduced airway bronchodilator reserve

The mechanism behind this risk is distinct from classical allergic asthma: the Wu et al. 2007 study found that GSNOR SNPs were not associated with degree of atopy (total IgE, skin-prick positivity). Rather, the ADH5 variant affects airway smooth muscle tone directly — through GSNO availability — rather than through IgE-mediated mast cell activation. This means the A-allele haplotype represents a non-atopic risk pathway to asthma, where the airway can be hyperresponsive even in the absence of elevated IgE or allergen sensitisation.

Formaldehyde exposure is a specific aggravating factor: ADH5/GSNOR also catabolises S-hydroxymethylglutathione (the formaldehyde-glutathione adduct), and high formaldehyde load competes for enzyme capacity, worsening GSNO depletion. New furniture, pressed wood (MDF, particleboard), gas stoves, and tobacco smoke are common formaldehyde sources.

A pharmacogenomic consequence: GSNOR risk haplotype combined with ADRB2 Arg16 (rs1042713) predicts approximately 70% of non-response to albuterol in acute asthma. If you use or plan to use albuterol and also carry the relevant ADRB2 variant, this compound interaction is clinically relevant.